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Summary: Lovastatin and simvastatin which are very potent cellular cholesterol biosynthesis Inhibitors,
significantly affect the plasma lipoprotein concentration.
After incubation of plasma with 14C-labelled compounds, radioactivity was found in all lipoprotein fractions
but mainly (40%) in high density lipoprotein (HOL), and in the lipoprotein-deficient plasma fraction
(20—30%). Dr g-treated lipoproteins showed reduced electrophoretic mobility on cellulose acetate in com-
parison with control lipoproteins. The lovastatin-treated low density lipoprotein (LDL) displayed 28%
increased fluidity in comparison with control LDL. The immunoreactivity of drug-treated LDL with mono-
clonal antibody directed towards the LDL receptor binding domains (B1B6) was significantly less than that
of control LDL, suggesting reduced binding to the LDL receptor. When drug-treated LDL was incubated
with J-774 A. l macrophage-like cell line, its binding (at 4 °C) was 28% less than that of control LDL, whereas
a substantial increase in the cellular cholesterol esterification rate (by 83% with lovastatin and by 67% with
simvastatin) was noted. Similarly, the degradation of lovastatin and simvastatin-treated LDL by macrophages
was 87 — 89% greater than that of control LDL. The "apparent Vmax" for the macrophage degradation of
lovastatin-treated LDL was 70% greater than that for control LDL. Thus, both drugs may have a dual effect
on the macrophage uptake of LDL; they may increase the number of LDL receptors on the cell surface, but
they may also reduce the affinity of LDL for its receptor, the former being the major effect. If the in vitro
changes caused by drug-treated LDL also occur in vivo, then the cellular uptake of LDL and plasma
cholesterol concentration could be determined by the magnitude of each of the opposing effects of the drugs.
Introduction Methode
Lovastatin, a potent hypocholesterolaemic dr g has Experimental procedure
a profound effect on plasma lipoprotein composition Whole plasma was incubated for l h at 37 °C with 0.1 — 100
and concentration (l -4). Lovastatin inhibits cellular F™1/1 ofunlabelled lovastatin or s nvastatm or with 20 GBq/1
, , , . , ' . ' , . Γ t. r [butanoate-l-14C] Mevacor (lovastatin) with specific radioac-
cholesterol biosynthesis and mcreases the number of
 tivity of 1A MBq/mg Or with [butanoate -1-'4C] Zocor (sim-
low density Upoprptehl (Lt>L) receptors on the sur- vastatin)ι with a similar concentration and with a similar specific
face Of cells (5). Plasma Concentration of LDL JS radioactivity. Lipoproteins were then separated by discontin-v
 ' : — . uous density gradient idtracentnfugation (6). Lipoprotems were
determined by the LDL receptor activity which is the
 also treated directly in some experiments with 100 μιηοΐ/ΐ of
result of the number of the receptors s well s the unlabeUed or labelled drugs for l h at 37 °C prior to Separation
affinitv of the iinot>rotems for these receptors The bV ultracentrifugation. Lovastatin was solubilized in dimethyl4inniiy 01 ine lipoprotems lor mese recepiorb. ine
 sulplloxide (DMSO), whereas simvastatin was solubilized in
present st dy was undertaken to find out whether
 ethanol. Control LDL preparations incubated under sim ar
lovastatin s weM s simvastatin bind to plasma lipo- conditions with the appropriate solvents were always used for
proWns and „bether such ta..rac<ion ff«,«, 4= ΪΪ^ΑΑΑ^ΚΤ'ΑϊίϊΑΚ
physico-chemical properties of the ilipoprotems and
 during clinical dosage r nge from 0.1 to 1.0 μιηοΐ/ΐ (7, 8). The
their Interaction with cells. plasma concentration of the drug is afiected by its absorption
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ralc, its time in the intestine s well s by its rapid passagc
through ihe liver, its high metabolic rate and its short plasma
half lifc. The drugs were a generous gift from Merck Sharp
and Dohmc Research Laboratories (Rahway N. J., U. S. A.).
Lipoproteins
Lipoprotein electrophoresis was carried out on cellulose acetate
(9), on sodium dodecyl sulphate (SDS) polyacrylamide gels (10)
and on non-denatured gradient gels (11). Protein in the lipo-
proteins and the cells was determined by the Lowry method
(12). Lipoprotein cholesterol was measured with the enzymatic
kit (Sigma Co., St. Louis, MO) and phospholipids, by the
method of Bartleit (13). Lipoprotein oxidation was measured
by the thiobarbituric acid reactive substances assay (14).
Solid phase competitive binding radioimmunoassay
LDL, drug-associated LDLs and LDL incubated with the ap-
propriate solvents (control LDLs) were assayed in competitive
displacement assays on microtitre plates (15). The plates were
coated with 140 μΐ of 10 mg/1 purified monoclonal antibody
B1B6 (this antibody is directed towards the LDL receptor
binding domains on apolipoprotein B-100 and mapped to
amino acid residues 3114—3606; it was a generous gift from
Drs. G. Schonfeld and E. Krul, Washington Univ., St. Louis,
MO, U. S. A.). Wells were blocked with 30 g/l bovine serum
albumin — phosphate buffered saline. Serial dilutions of the
lipoproteins were added followed by the addition of a constant
amount of [125I]LDL (500 ng). After incubation for 4 h at room
temperature, the wells were washed 3 times with phosphate-
buffered saline, and binding (B) was determined. The maximum
binding (B0) was determined in wells where competing lipopro-
tein was not added. The results are expressed s the B/B0 ratio
and each point is the mean of two measurements (CV < 10%).
Lipoprotein f luidi ty
The steady-state fluorescence polarization of diphenylhexa-
triene incoφOΓated into lipoproteins was measured (16). The
analysis was carried out with a spectrofluorimeter equipped
with polarizers. Lipoproteins (protein = 50 mg/1) were incu-
bated with 100 μπιοΙ/1 diphenylhexatriene for 30 minutes at
37 °C. Fluorescence polarization measurements were carried
out at various temperatures and the anisotropy was determined.
The anisotropy parameter is inversely related to the fluidity
and is given s [(r0/r — 1)] where r is the fluorescent anisotropy
obtained from the polarization analysis and r0 is the upper
theoretical limit of the anisotropy.
Cells
Monolayer cultures of J-774A.1 murine macrophage-like cells
were grown and maintained in Dulbecco Modified Eagles Me-
dium (DMEM) supplemented with a 0.1 volume fraction of
fetal bovine serum, penicillin (100 · 103 U/l), streptomycin (100
mg/1) and glutamine (2 mmol/1). The cells were fed twice every
week. Human skin fibroblasts were cultured form punch biop-
sies of the skin of the anterior thigh from normal volunteers.
Subcultures were used between passages 4-12. The cells were
plated at 5 χ ΙΟ5 cells/35-mm dishes in DMEM supplemented
with a 0.1 volume fraction of fetal calf serum, 100 · 103 U/l
penicillin, 100 mg/1 streptomycin, and 2 mmol/1 glutamine.
After five days in culture, the medium was changed to DMEM
supplemented with a 0.1 volume fraction of human lipoprotein-
deficient serum (d > 1.25 kg/l, prepared by ultracentrifugation)
for 48 h to upregulate cellular LDL receptors.
Macrophage cholesterol esterification
Lipoproteins (protein = 25 mg/1) were incubated with the cells
for 5 hours at 37 °C in the presence of 370 MBq/1 of 3[H]oleic
acid (0.27 nmol/l, 83 nmol oleate per mg albumin). At the end
of the incubation, cellular lipids were extracted with hexane-
isopropanol (3 + 2, by vol.) and the cholesteryl ester was sep-
arated by thin layer chromatography (hexane : ether : acetic
acid, 130 H- 30 + 1.5, by vol.), scjaped into vials containing 15
ml scintillation fluid and counted m a beta scintillation counter
(17).
Lipoprotein binding to macrophages and fibro-
blasts
High affinity binding of I25I-labelled lipoproteins to cells was
studied in the absence or preserice of 50 fold excess of unlabelled
lipoproteins after 4 h of incubation at 4 °C. Cells were washed
(x4) with phosphate-buffered saline, extracted with 0.1 mol/1
NaOH (l h at room temperature) and the bound radiolabelled
LDL was counted in a scintilation counter.
Lipoprotein degradation by macrophages and fi-
broblasts
Lippprotein degradation by cells was measured following in-
cubation of [125I]LDL, lovastatin-associated [125t]LDL, and sim-
vastatin^associated [125I]LDL with cells for 5 h at 37 °C. The
hydfolysis of LDL protein was assayed in the incubation me-
dium by measurement of tnchloroacetic acid-soluble, non
iodide radioactivity (17). Cell-free LDL degradation was min-
imal and was subtracted from total LDL degradation. The cell
layer was washed three times with phosphate-buffered saline
and extracted by a l h incubation at room temperature with
0.5 ml of 0.1 mol/1 NaOH for measurement of protein.
Statistics
Results are given s mean ±
by the Wilcoxon rank test.
S. D. Significance was analysed
Results
The partition of lovastatin and simvastatin among
the various plasma lipoproteins was studied by incu-
bating whole plasma from iiormolipidaemic subjects
for l h with 10 μιηοΐ/ΐ of 14C-labelled lovastatin or
simvastatin, followed by lipoprotein Separation (using
discontinuous density gradient ltracentrifugation).
Table l demonstrates that the largest fraction of ra-
dioactivity (38%) was associated with high density
lipoproteins (HDL). The drugs were also assoqiated
with very low density lipoprotein (VLJDL) and l w
density lipoprotein (LDL), while 20-30% of the ra-
dioactivity was recovered in the lipoprotein-deficient
plasma fraction. When expressed per mg pf protein,
the drug binding capacity was similar for all lipopro-
teins (tab. 1).
The binding capacity of simvastatin for HDL, LDL
and VLDL was, however, 3, 4 and 6 times greater,
respectively^ than that of lovastatin (tab. 1). The ad-
dition of 10 fold excess unlabelled lovastatin or sim-
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Tab. l. Distribution of lovastatin and simvastatin among
plasma lipoproteins.
Lovastatin
VLDL
LDL
HDL
LPDP
ng/mg
protein
244
303
319
16
%
12
20
38
30
Simvastatin
ng/mg
protein
1400
1236
824
11
%
15
25
40
20
Whole plasma was incubated with 20 MBq/1 of 14C-labelled
lovastatin or simvastatin (100 μιηοΐ/ΐ) for l h at 37 °C, followed
by lipoprotein Separation using discontinuous density gradient
ultracentrifugation. Radioactivity was determined in each frac-
tion and expressed s percent of total radioactivity (%) or s
ng of drug associated with l mg of lipoprotein protein. Results
are the means of triplicates; they are representative of the results
of 3 experiments which varied by less than 10%. VLDL — very
low density lipoprotein. LDL — low density iipoprolein. HDL
— high density lipoprotein. LPDP — lipoprotein deficient
plasma.
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Fig. l. Electrophoresis of lovastatin-treated lipoproteins on cel-
lulose acetate. Lipoproteins were stained with oil red
O. VLDL, very low density lipoproteins. LDL, low
density lipoproteins. HDL, high density lipoprotein.
Tab. 2. Distribution of lovastatin among plasma lipoproteins:
drug concentration study.
Lovastatin
concentration
(μιηοΐ/ΐ)
0.01
0.1
1.0
10
% of total
VLDL
10
6
6
15
radioactivity
LDL
15
18
18
20
HDL
30
35
38
33
LPDP
45
41
38
32
The study was carried out under similar conditions to those
described in table 1.
vastatin to the plasma for the period of incubation
with the labelled dr g resulted in 45% and 31%
reduction in LDL-associated drug respectively, sug-
gesting specific drug binding to the lipoproteins. To
study the effect of lovastatin at concentrations below
those present in plasma during clinical dosage, plasma
was incubated for l hour with labelled lovastatin at
concentrations of 0.1, 1,0 and 10 μτηοΐ/ΐ, and the
distribution of the radioactivity was determined (tab.
2). The results revealed a similar pattern to that shown
with 100 μπιοΐ/ΐ of lovastatin (tab. 1). The levels of
LDL cholesterol, phospholipids and protein were un-
changed after lipoprotein incubation with the drugs
(data not shown).
In lipoprotein electrophoresis ori cellulose acetate,
VLDL, LDL and HDL (protein = l g/l) that had
been incubated with 100 μιηοΐ/ΐ lovastatin showed a
substantially reduced electrpphoretic mobility (fig. 1).
Electrophoretic mobility of 14C-labelled drug-treated
lipoproteins revealed that the radioactivity was asso-
ciated with the lipoproteins bands. The drugs did not
affect LDL size, or the integrity of apolipoprptein B-
LDL + DMSO + Ethanol + Lovastatin + Simvastatin LDL
Fig. 2. Electrophoresis of drug-treated LDL on cellulose ace-
tate. DMSO, dimethyl sulphoxide (used for solubiliza-
tion of lovastatin). Ethanol is used for solubilization of
simvastatin.
100, as analysed by non-denatured gradient gels and
by SDS polyacrylamide gel electrophoresis (data not
shown). Both lovastatin- and simvastatin-associated
LDL, like native LDL, showed minimal oxidation
(0.3 — 0.7 nmol malondialdehyde equivalents per mg
protein). Simvastatin- and lovastatin-treated LDL
displayed reduced electrophoretic mobility (fig. 2) and
this could not be attributed to the drug solvents
(DMSO or ethanol, fig. 2). Pravastatin however,
which is an open acid molecule, did not affect lipo-
protein electrophoretic mobility (data not shown).
Lovastatin was found to affect lipoprotein fluidity,
mainly that of LDL. The fluidity of lovastatin-treated
LDL was increased by 28% in comparison with the
fluidity of control LDL (fig. 3). The effect of the
drugs on LDL immunoreactivity was tested using
monoclonal antibody Bl B6, which is directed towards
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 29,1991 / No. 10
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2.0
1.0
LDL
3.18 3.20 3.22 3.24 3.26 3.28
1/T[103K'1]
3.30
Fig. 3. Fluidity of lovastatin-treated lipoprotein. Lipoproteins
(l g of protein per litre) were incubated without (o) or
with (a) 100 μπιοΐ/ΐ lovastatin for l h at 37 °C. The
fluidity of the lipoprotein was then measured s de-
scribed under Methods. The fluidity is inversely related
to the anisotropy parameter (which is expressed under
several teraperature points). Results are representative
of 3 different experiments.
the LDL receptor binding domains on apolipoprotein
B-100. Figure 4 demonstrates the reduced immuno-
reactivity of lovastatin- and simvastatin-associated
LDLs in comparison with control LDL treated with
either DMSO or ethanol.
ED —25 vahies (the concentration of unlabelled li-
poprotein required to reduce the immuiioreactivity to
25% of control) for lovastatin- and simvastatin-
treated LDL were 27 and 25 mg/1 compared with 12
and 9 mg/1 for the appropriate controls, respectively
(fig. 4). Analysis of drug binding to macrophages
revealed that both lovastatin and simvastatin bind to
macrophages (tab. 3).
Tab. 3. Macrophage binding of lovastatin or simvastatin-
treated LDL.
Drug Macrophage-associated drug
(% of added radioactivity)
A. 100 μπιοΐ/ΐ
Lovastatin
Lovastatin-LDL
Simvastatin
Simvastatiri^LDL
B. l μιήοΐ/ΐ
Lovastatin
Lovastatin-LDL
Simvastatin
Simvastatin-LDL
0.2 ± 0.01
11 ±'0:9
0.4 ± 0,04
19 ± 1.3
0.8 ± 0.2
9.5 ± 0.7
1.4 ± 0.4
16.7 ± 2.2
J-774A.1 macrophages were incubated for l h at 37 °C with
14[C]lovastatin, 14[C]simvastatin or LDL (protein = 25 mg/1)
associated with either 14C-labelled lovastatin or with 14C-la-
belled simvastatin. Drug-associated LDLs were prepared by
inc bation of plasma with the labelled drugs followed by Sep-
aration. Cells were washed (x3) with phosphate-buffered saline
and cell-associated radioactivity was determined. Drugs were
used at two c ncentrations: A — 100 μτηοΐ/ΐ, B — l umol/1.
Results are mean ± S. D. of 3 experiments.
At lower, more physiological c ncentrations, how-
ever, drug binding to the cells increased; simvastatin
binding to the cells was about twice that of lovastatin.
The binding efficiency of each drug was substantially
higher when it was introduced to the cells in associ-
ation with LDL, rather than s the free compound
(tab. 3).
The effect of drug treatment of LDL on its cellular
binding, uptake and degradation were studied in J-
774 A. l macrophage-lile cell Hne and in human skin
100*-
60 80 100 w 0 20
Lipoprotein concentration (log,mg/l l
60 •80 "100
Fig. 4. Immunoreactivity of drug-treated LDL against the monoclonal antibody B1B6. Microtitre wells were coated with the
monpclonal antibody B1B6 (10 mg/1) for 18 hours. The assay was carried out s described under Methods using serial
dilutions of LDL, control LDL (with the appropriate solvent) and drug-asspciated LDL. The results are expressed s the
ratio of the mdividual radioactivity counts (B) to those obtained in the absence of competitor (B0).
a) Lovastatin b) Simvastatin
o- LDL *_*
 LDL
o-o LDL + DMSO O-Q LDL + ethanol
Δ - Δ LDL + lovastatin Δ ~ Δ LDL -h simvastatin
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 29,1991 / No. 10
Aviram et al: Interaction among lovastatin, lipoproteins and macrophages 661
Tab. 4. Macrophage uptake and degradation of lovastatin- or
simvastatin-treated LDL.
LDL
LDL-DMSO
LDL-lovastatin
Cholesterol
esterification
(nmol/mg cell
protein per 5 h)
0.8 ± 0.2
0.5 ± 0.3
1.5 ± 0.4*
Lipoprotein
degradation
(ng/mg cell
protein per 5 h)
1335 ± 133
1411 ± 128
2693 ± 303*
(100 μιηοΐ/ΐ)
LDL-lovastatin
(l μηιοΐ/ΐ)
LDL-Ethanol
LDL-simvastatin
(100 μιηοΐ/ΐ)
LDL-simvastatin
(l μιηοΐ/ΐ)
1.2 ± 0.2*
0.6 ± 0.3
1.8 ± 0.3*
1.1 + 0.2*
2099 ± 195*
1489 ± 73
1993 ±211*
2011 ± 101*
J-774A.1 macrophage cell line (106/16 mm well) were incubated
with 25 mg of protein per litre of unlabelled liproproteins or
with 125I-labeiled lipoproteins (that were previously treated with
drugs or with solvente) for 5 h at 37 °C. Cellular cholesterol
esterification rate and macrophage degradation of the lipopro-
teins were analysed s described under Methods. The lipropro-
teins were pretreated with the drugs (100 μιηοΐ/ΐ or l μηιοΐ/ΐ)
for l hour at 37 °C followed by LDL Separation (by ultracen-
trifugation). Control LDLs were similarly prepared but they
were treated with the appropriate solvents instead of drugs.
Results are mean ± S. D. of 3 experiments *p < 0.01 (vs. the
appropriate control). DMSO — Dimethylsulphoxide.
fibroblasts. Lovastatin-treated [1?5I]LDL (protein
= 25 mg/1) binds at 4 °C to macrophages 28% less
than control LDL (350 + 37 Vs. 448 + 49 ng/mg cell
protein respectively, n = 3). Similarly, the binding of
lovastatin-treated LDL to human skin fibroblasts was
reduced by 27% (from 839 ± 39 to 611 ± 44 ng/mg
cell protein, n == 3). The cellular uptake of lipopro-
teins (protein = 25 mg/1)* s assessed by the macro-
phage cholesterol esterification rate, however, showed
a 83% and 67% increased uptake of lovastatin (100
μmQl/l)-treated LDL and simvastatin-treated LDL
respectively, in comparison with the control LDLs
(tab. 4). Similarly, the macrophage degradation of
these drug-associated LDLs increased by 89% and
87%, respectively (tab. 4). Similar effects were ob-
served when a drug concentration of only l μιηοΐ/ΐ
was used (tab. 4). In human skin fibriblasts, the ceU
lular degradation of control LDL and lovastatin-
treated LDL (f 00 μιήοΐ/ΐ and l μπιοΐ/l of lovastatin)
were 1991 ± 101, 3893 ± 233 and 2713 ± 188 ng/
mg cell protein respectively (n = 3). Figure 5 shows
lipoprotein dose response curves for the macrophage
degradation of lovastatin-associated LDL and of na-
tive LDL. At all lipoprotein concentrations studied,
1600
σ>
!
 1200
800
U)0
£, Z
+ S. 20
=,5 10
- < o 0.02 0.04 OJ06
1/[S] [mg/l]"'
X
Upopro,L substrate concenuat.on tj,]
100
Fig. 5. A dose response curve of macrophage degradation of
lovastatin-associated LDL (o) and native LDL (o).
125I-LDL (l g of protein per litre) was incubated with
100 μπιοΐ/ΐ lovastatin for 2 h at 37 °C and separated by
ultracentrifugation prior to its addition (25 mg of pro-
tein per litre) to J-774A.1 macrophages. Cellular deg-
radation of increasing concentrations of the lipoproteins
was determined s described under Methods. Results
are the means of triplicates; they are representative of
the results of two experiments which varied by less than
10%. The lipoprotein Substrate concentration [S] refers
to protein, mg/1.
the cellular degradation of lovastatin-associated-LDL
was substantially higher than that of the untreated
lipoproteins (fig. 5). Analysis of the data by the Li-
neweaver-Burk plot revealed that the "apparent Vmax"
for lovastatin-associated LDL was 1.7 times higher
than that for native LDL, with no significant effect
on "apparent Km" (fig. 5, insert). Macrophage deg-
radation of lovastatin-associated [125]LDL (LDL-
LOV, protein =10 mg/1) was substantially reduced
by 500 mg/1 of unlabelled lovastatin-associated LDL
(from 345 ± 35 to 75 ±17 ng/mg cell protein per
5h). When native unlabelled LDL or acetyl LDL
were used at similar concentrations, the cellular deg-
radation of lovastatin-associated [125I]LDL was 89
± 24 and 337 ± 29 ng/mg cell protein, respectively,
suggesting that lovastatin-associated LDL binds to
the macrophage LDL receptor and not to the scav-
enger receptor.
Discussion
The present study demonstrates the binding of lovas-
tatin and siinvastatin to plasma lipoproteins over a
wide r nge of concentrations including those found
in plasma during clinical dosage. Such drug binding
was shown to affect lipoprotein physico-chemical
characteristics, including reduced lipoprotein electro-
Eur. J. Clin. Chem. Clia. Bioohein. / Vol. 29,1991 / No. 10
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phoretic mobility, increased fluidity and reduced im-
munoreactivity witli the monoclonal antibody B1B6,
which is directed against the LDL receptor binding
domains on apolipoprotein B-100. Uptake of drug-
associated LDL by macrophages and fibroblasts was
higher than that of native LDL. Even though the
drugs may reduce the affinity of LDL for the LDL
receptor, the net effect of the drug was to increase
cellular uptake of the lipoprotein. This effect resulted
from the increased number of LDL receptors on the
cell surface which more than compensated for the
reduced binding affinity of drug-treated LDL for the
LDL receptor.
It is of interest that simvastatin showed increased
binding to lipoproteins and macrophages in compar-
ison with lovastatin. This may be related to the ad-
ditional methyl group on the simvastatin molecule
(l 8). Lovastatin and simvastatin, which are adminis-
tered äs the lactone forms, are present in the systemic
circulation. both äs open chain acids (62%) and äs
closed-ring lactones (38%), both of which are poten-
tially active (7). In the present study we used the
lactone forms of the drugs. Although the active form
of lovastatin is the acid, there are also many other
active metabolites (19). The presence of non-metab-
olized lovastatin in the circulation (äs the lactone)
can affect cellular metabolism of LDL via mechanism
other than Inhibition of cellular cholesterol synthesis.
Cellular uptake of the drugs may also result in the
hydrolysis of the lactone to the acid form, thus causing
cellular cholesterol biosynthesis Inhibition with sub-
sequent increased synthesis of receptors for LDL.
Recently it was shown that both lovastatin and sim-
vastatin, when used in the lactone form, inhibited
cholesterol biosynthesis in human monocyte-derived
macrophages (20).
The molecular size of the drug-treated lipoproteins
was unchanged according to gradient gel electropho-
resis analysis under non-denaturing conditions. Both
drugs, however, reduced the electrophoretic mobility
of LDL; this may be due to a changed conformation
of the lipoprotein surface and the altered availability
of charged surface phospholipids. It is well docu-
mented that the Charge of LDL affects its uptake by
macrophages (21 —23).
Increased uptake of LDL by macrophages has been
demonstrated following lipoprotein oxidation (22,
23). In our study, however, the drug did not affect
the oxidation state of LDL. Furthermore, LDL apo-
lipoprotein B-100 fragmentation, which is associated
with lipoprotein oxidation (22-24), did not take
place in drug-associated LDL.
LDL fluidity was recently shown to be significantly
reduced following incubation with platelet secretory
products (25). Lipoprotein fluidity depends on its
cholesterol to phospholipid ratio and on its fatty acid
composition (26). Since the cholesterol and phospho-
lipid contents were not changed in drug-associated
LDL, it is possible that drug binding to the lipoprotein
is associated with its interaction with phospholipid
fatty acids. The increased lipoprotein fluidity ob-
served in lovastatin-associated LDL may contribute
to the enhanced cellular uptake of drug-associated
LDL. Increased LDL fluidity following lovastatin
therapy in hypercholesterolaemic patients was re-
cently demonstrated in our laboratory (Aviram, M. et
al., unpüblsihed observation).
Both drugs reduced the immunoreactivity of LDL
towards monoclonal antibody B1B6, which recog-
nizes epitopes at the LDL receptor binding domains
of apolipoprotein B-100. This reduced immunoreac-
tivity of the modified LDL may be related to the
changes in lipoprotein Charge, äs suggested from the
reduction in its electrophoretic mobility. Whereas the
free drugs bind poorly to macrophages and fibn>
blasts, they bind substantially to these cells when
associated with LDL. This pheüomenon is the result
of the high binding affinity of the lipoprotein for cells
(27). It is possible that in vivo LDL is responsible for
delivering the drugs into the cells. The hypocholester-
olaemic effect of the drugs is related to their ability
to inhibit the rate-limiting enzyme of cholesterol bio-
synthesis, hydroxymethylglutaryl-coenzyme A reduc-
tase (HMG-CoA reductase) (l, 2). This effect in turn
results in increased synthesis of of LDL receptors
(28), and thus more LDL can be taken up by the cells
and plasma cholesterol is reduced. The present study
showed that the "apparent Vraax" for lovastatin-as-
sociated LDL was higher than that for control LDL,
suggesting that the drug increased the number of LDL
receptors on the cell surface (probably following its
intracellularconversion to the active acid form). From
the reduced immunoreactivity of drug-associated
LDL with the monoclonal antibody B1B6 and from
its reduced cellular binding affinity, it can be expected
that its uptake by the macrophage LDL receptor will
be also reduced. In our study however, drug-associ-
ated LDLs were taken up and degraded by macro-
phages and by fibroblasts at increased rate in com-
parison with native LDL. Drug binding to LDL may
cause conformational changes in apolipoprotein B-
100 (äs suggested from the reduced immunoreactivity
of drug-associated LDL with the monoclonal anti-
body B1B6) and this in turn could reduce the affinity
of the lipoprotein for the cellular LDL receptor. On
Eur. J. Clin. Chem. Clin. Biochem. / VoL 29,1991 / No. 10
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the other band, the ability of LDL to effectively
deliver drug into the cells via the LDL receptor path-
way, contributes to a specific Inhibition of HMGCoA
reductase with a subsequent reduction in cellular cho-
lesterol biosynthesis and an induction of LDL recep-
tor synthesis. This latter effect of lovastatin, which
results in an increased number of LDL receptors on
the cell surface, is the major effect of the drug on the
cellular uptake of LDL, since the net effect of lovas-
tatin-associated LDL was to increase the cellular up-
take and degradation of the lipoprotein. Thus, the
reduced affinity of lovastatin-associated LDL for the
LDL receptor might contribute far less to the cellular
uptake of the lipoprotein than the increased number
of LDL receptors. In certain pathological conditions,
the magnitude of the opposing effects of lovastatin
on LDL uptake by macrophages would determine the
amount of cellular cholesterol accumulation.
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